目的:统计肺癌患者治疗前后癌性贫血发生率,分析其危险因素,探讨癌性贫血对肺癌患者生活质量(QOL)和预后的影响。方法:回顾性分析我院240例肺癌患者的临床资料,统计其治疗前后癌性贫血的发生率,分析其与性别、年龄、临床分期、PS评分、血清白蛋白水平和化疗的关系。应用QOL量表EORTCQLQ-C30中文版评价癌性贫血对肺癌患者QOL的影响,并探讨其对肺癌患者生存的影响。结果:240例肺癌患者,总体癌性贫血发生率为52.5%,治疗后癌性贫血发生率明显高于治疗前(15.8%,P=0.000)。化疗者癌性贫血发生率明显高于未化疗者(57.7%vs36.2%,P=0.004),化疗后明显高于化疗前(57.7%vs19.2%,P=0.000)。单因素和Logistic多因素回归分析均证实,年龄、临床分期、血清白蛋白水平及化疗是影响癌性贫血的危险因素(P均<0.05)。性别和病理类型与癌性贫血无关。癌性贫血明显影响肺癌患者的QOL;发生癌性贫血的患者生存期明显短于未发生癌性贫血者(9个月vs14个月,P=0.000)。Cox多因素回归分析证实,癌性贫血、临床分期、PS评分是影响肺癌患者预后的独立因素。结论:肺癌患者有较高的癌性贫血发生率,癌性贫血与年龄、临床分期、血清白蛋白水平及化疗密切相关,年龄越大、分期越晚,癌性贫血发生率越高越重。癌性贫血不但影响肺癌患者的QOL,还影响其预后。 Objective: To analyze the incidence of cancer anemia before and after treatment of patients with lung cancer, analyze its risk factors and explore the influence of cancer anemia on quality of life (QOL) and prognosis of lung cancer patients. Methods: The clinical data of 240 lung cancer patients in our hospital were retrospectively analyzed. The incidence of cancer anemia before and after treatment was calculated. The relationship between gender, age, clinical stage, PS score, serum albumin level and chemotherapy was analyzed. To evaluate the effect of cancer anemia on QOL in patients with lung cancer by using the QOL EORTCQLQ-C30 Chinese version and explore its impact on the survival of patients with lung cancer. Results: The overall incidence of cancerous anemia in 240 patients with lung cancer was 52.5%. The incidence of cancerous anemia after treatment was significantly higher than that before treatment (15.8%, P = 0.000). The incidence of cancer-related anemia was significantly higher in patients with chemotherapy than in those without chemotherapy (57.7% vs36.2%, P = 0.004), significantly higher after chemotherapy than before chemotherapy (57.7% vs19.2%, P = 0.000). Univariate and Logistic multivariate regression analysis confirmed that age, clinical stage, serum albumin level and chemotherapy were the risk factors of cancerous anemia (all P <0.05). Sex and pathological type have nothing to do with cancer anemia. Cancerous anemia significantly affected QOL in patients with lung cancer; patients with cancerous anemia had significantly shorter survival than those without cancerous anemia (9 vs 14 months, P = 0.000). Cox multivariate regression analysis confirmed that cancer anemia, clinical stage, PS score is an independent factor affecting the prognosis of lung cancer patients. Conclusion: The incidence of cancerous anemia in patients with lung cancer is higher. The incidence of cancerous anemia is closely related to age, clinical stage, serum albumin level and chemotherapy. The older, the later stage, the higher the incidence of cancerous anemia. Cancerous anemia not only affects QOL in patients with lung cancer, but also affects its prognosis.